| Welcome
to the ninth issue of PharmaView!
Pharmaceutical Marketers
are facing increasing pressures: increasing competition; squeezed
margins; shrinking budgets; more to do and less time to do it. It’s
becoming difficult to work any harder, and of course it's always
better to work smarter. Therefore we bring you the PharmaView.
PharmaView is a biweekly
educational and informative newsletter for improving readers’
marketing knowledge and reporting the latest news in the pharma
industry. It also provides great opportunities to exchange ideas,
network and be recognized among your peers in the
industry.
Through PharmaView, you can:
Learn peer’s experience
in pharma marketing
Stay in touch with what’s
happening in pharmaceutical marketing today
Be on the pioneering edge
of pharmaceutical marketing
Have networking / idea
exchange opportunities
 About
Us
Integrating local knowledge with international
perspective, Consultech Co. Ltd. offers its clients and
prospects one-lstop solutions with sales and marketing consultancy,
advertising and promotion strategies.
Consultech is an
affiliate company of Omnicom, the world's largest advertising and
communications holding company
Creative Design: Case study of
Genentech Oncology Visuals
Novartis Gets Tentative Exforge
Approval
Drug
developer Novartis said Friday the Food and Drug Administration gave
its hypertension drug Exforge tentative approval.
Dec 22, 2006
FDA Approves Byetta (exenatide)
Injection for Expanded Combination Use
Millions of People Using Thiazolidinediones Now Have New Treatment
Option to Manage Type 2 Diabetes
Dec 22, 2006
Using eLearning for Customer
Acquisition
In
this industry, it is obvious that education is the key to the sales
process. If you are already using eLearning for sales training, you
know how effective this technology is to prepare your sales force
Medical Education Success in a
Compliant Market Place– Innovation and Marketing Prowess are
Critical
Every pharmaceutical and biotech company is evaluated on its ability
to innovate in terms of developing and commercializing its pipeline.
Unfortunately, today’s government regulation risk is, in many cases,
bringing this innovation to a screeching halt.
The Year in Review: Pfizer Shifts
Gears
Shares of Pfizer Inc. have risen about 9 percent this year as the
world's largest drug maker tried to transform itself into a more
nimble organization.
Dec 26, 2006
Analyst: Big Pharma Wields Axe
Bad news for drug sales reps: firing you may be a dominant industry
theme for 2007.
Dec 21, 2006
Please feel free to offer your opinions and advices about
PharmaView in order to better our services. Should you have any
comments, or if you want to unsubscribe from PharmaView,
please send us an email:
pharmaview@Consultech.com.cn . Thank
you!
| 
